Fri, Jul 25, 2014, 2:59 PM EDT - U.S. Markets close in 1 hr 1 min


% | $
Click the to save as a favorite.

Vertex Pharmaceuticals Incorporated Message Board

  • crossroads4040 crossroads4040 Nov 2, 2012 10:45 AM Flag

    The problems with the cc

    First, while Ian Smith and Peter Mueller were articulate about the business, Jeff Leiden is clearly just a figurehead with no detailed knowledge of the pipeline. It was actually embarrassing that all he could do was repeat that all the pieces were now in place for the hep c program over and over.
    Second, when pressed about 2013 cash flow , Ian Smith just dodged the question and couldn't reiterate previous guidance for positive cash flow in2103/2014.
    Third, vx-222 wasn't mentioned until the q&a. History shows that when they stop mentioning a molecule it's dead.
    Fourth, there was clearly a lot of suspicion among analysts about vx-661; which now we won't get data for until " 1h13". Maybe it's my imagination, but aren't they constantly delaying this. When pressed, they wouldn't just come out and say they were excited about 661; they actually talked more about 2nd generation correctors. I would think this is behind the GS downgrade today.

    When you miss earnings this badly for 2 straight quarters and essentially admit you will lose money until the cf program is more advanced, you have to come out swinging and defend the program. They failed to do that.

95.78+0.01(+0.01%)2:57 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.